Objective: The prominent histopathological feature of the amyotrophic lateral sclerosis (ALS) is the presence of intracellular inclusions in degenerating neurons and their axons. The appearance and localization of these pathological structures depend on an aggregated protein that forms their scaffold. We investigated if c-synuclein, an aggregation-prone protein highly expressed in healthy motor neurons, and predominantly localized in their axons and synaptic terminals is involved in ALS pathology. Methods: Immunostaining of histological sections and sequential protein extraction from postmortem neural samples followed by immunoblotting. Results: Immunohistochemical screening revealed a subset of sporadic (9 of 31) and familial (8 of 23) ALS cases with a novel type of pathology characterized by the accumulation of c-synuclein in distinct profiles within the dorsolateral column. Sequential fractionation of proteins from the spinal cord tissues revealed detergent-insoluble c-synuclein species specifically in the dorsolateral corticospinal tracts of a ALS patient with c-synuclein-positive profiles in this region. These profiles are negative for protein markers commonly found in pathological inclusions in the spinal cord of ALS patients and most probably represent degenerated axons of upper motor neurons that have lost their neurofilaments. A subset of these profiles was found in association with phagocytic cells positive for Mac-2/Galectin-3. A smaller subset of studied ALS cases (4 of 54) contained large cytoplasmic inclusions in the cell body of remaining spinal motor neurons. Interpretation: Our observations suggest that pathological aggregation of c-synuclein might contribute to the pathogenesis of ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease characterized by the selective loss of discrete populations of upper and lower motor neurons. A histopathological hallmark of both familial (fALS) and the more common sporadic (sALS) forms of the disease is the presence of distinctive intracellular inclusions in degenerating neurons and their axons. Formation of these pathological structures has been linked with the accumulation and aggregation of several proteins, including those mutated in fALS, namely SOD1, 1 TDP-43, 2 FUS/TLS, 3, 4 neurofilament subunits, 5 optineurin, 6, 7 ubiquilin-2 8 and even dipeptide products of unconventional repeat-associated This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
non-ATG initiated translation of GGGGCC repeats in C9ORF72 locus. 9, 10 However, some proteins that are constituents of pathological inclusions have never been genetically associated with fALS or predisposition to sALS, examples include p38MAPK, 11 galectin-1, 12 Smad2/3, 13 RBM45 14 and p54nrb/NONO. 15 It is likely that other, yet to be identified proteins may be involved in ALS pathology.
c-Synuclein presents a feasible candidate for such a protein due to an auspicious combination of properties. Structurally it is closely related to a-synuclein and shares its ability to aggregate in vitro 16, 17 and in vivo, 18 which is believed to be a crucial trigger of neurodegeneration in asynucleinopathies. Motor neurons express high levels of c-synuclein, with the protein highly abundant in their axons, where it might affect organization of axonal cytoskeleton. [18] [19] [20] [21] Axonal or periaxonal accumulation of c-synuclein has been found to accompany major histopathological changes in several neurodegenerative diseases. [22] [23] [24] Finally, genetically unaltered c-synuclein aggregates, fibrillates and forms axonal and perikaryal inclusions when overexpressed in neurons of transgenic mice, which is coupled with progressive and selective loss of motor neurons and the development of motor deficiency. 18, 25 We therefore undertook a search for any evidence of c-synuclein pathology in patients with sporadic and familial ALS, a disease where such pathology has not yet been assessed, using a set of previously histopathologically characterized spinal cord samples.
Materials and Methods

Patient data and analysis of tissue samples
Human tissue samples were obtained from the MRC London Neurodegenerative Diseases Brain Bank and Sheffield Brain Tissue Bank. Consent was obtained from all subjects for autopsy, histopathological assessment and research in accordance with local and national Ethics Committee approved donation. For each case a detailed post-mortem histopathological report produced by a qualified pathologist was obtained after completion of the primary assessment of c-synuclein staining that was carried out blindly. The spinal cord tissues were histologically assessed from 31 cases of sALS (21 males, 10 females; mean ageAESEM 65.2 AE 1.9 years, mean postmortem delay AE SEM 34.7 AE 4.1 h), 17 cases of fALS with C9ORF72 expansion (nine males, eight females; mean age AE SEM 62.2 AE 2.2 years, mean post-mortem delay AE SEM 37.6 AE 7.6 h); three cases of SOD1-fALS (one male, two females; mean age AE SEM 53.7 AE 7.7 years, mean post-mortem delay AE SEM 27.7 AE 18.4 h), three cases of FUS-fALS (one male, two females; mean age AE SEM 34.3 AE 0.7 years, mean post-mortem delay AE SEM 38.3 AE 16.4 h), six Alzheimer's disease cases (three males, three females; mean age AE SEM 76.7 AE 4.4 years, mean post-mortem delay AE SEM 26.2 AE 8.5 h), one Lewy body dementia case (male; age 88 years, post-mortem delay 18 h), one Parkinson's disease case (male, age 74, post-mortem delay 10 h) and 13 control cases with no clinical history or histological evidence of neurodegeneration (eight males, five females; mean age AE SEM 68.7 AE 3.4 years, mean post-mortem delay AE SEM 46.5 AE 7.3 h). For details of ALS and control cases see Table 1 .
Primary antibodies
Anti-human c-synuclein rabbit-polyclonal SK109 antibody 21 was used at 1:250 dilution for immunohistochemistry, 1:100 dilution for immunofluorescence and 1:500 dilution for Western blotting. Anti-human c-synuclein goat-polyclonal E20 antibody (Santa Cruz Biotechnology Inc., Dallas, TX) was used at 1:100 dilution for immunohistochemistry and 1:250 dilution for Western blotting. To prove the specificity of c-synuclein staining some sections were immunostained with SK109 or E20 antibody preincubated for 1-h with purified recombinant human c-synuclein at 0.1 mg/mL concentration. Anti-ubiquitin mouse monoclonal Ubi-1 antibody (Zymed Laboratories Inc., South San Francisco, CA) was used at 1:100 dilution for immunohistochemistry and immunofluorescence. Anti-phospho(S409/410-2)TDP-43 rabbit-polyclonal antibody (Cosmo Bio Co. Ltd., Tokyo, Japan) was used at 1:3000 dilution for immunohistochemistry. For immunofluorescence, anti-neurofilaments mouse monoclonal SMI312 antibody (Covance, Princeton, NJ) was used at 1:100 dilution, anti-Mac-2/Galectin-3 mouse monoclonal B2C10 antibody (BD Pharmigen, Jose, CA) -at 1:100 dilution and anti-p62 mouse monoclonal clone 3 antibody (BD Pharmigen) -at 1:100 dilution.
Histological techniques
Eight-lm thick sections of 10% formalin-fixed paraffinembedded cervical and thoracic spinal cord and primary motor cortex were processed and immunostained as described previously. 18, 21 Immunohistochemical detection was carried out using Elite plus kits (Vector Laboratories, Burlingame, CA) and 3,30-diaminobenzidine as a substrate (Sigma-Aldrich, St. Louis, MO). For immunofluorescent detection anti-rabbit and anti-mouse secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 546 or Alexa Fluor 633 (Invitrogen, Carlsbad, CA) were used at 1:1000 dilution and images were collected sequentially on a Leica TCS SP2 laser scanning confocal microscope (Leica Microsystems, CMS, GmbH, Mannheim, Germany).
Sequential protein extraction
A previously described protocol 18 was used with minor modifications. Briefly, frozen neuronal tissues were homogenized in five volumes of high salt buffer (50 mmol/L Tris-HCl, pH 7.5; 750 mmol/L NaCl; 5 mmol/L EDTA) with protease inhibitors (Complete Mini from Roche Diagnostics Limited, Burgess Hill, UK) and centrifuged at 12,000g for 15 min at 4°C. The supernatant (PMS fraction) was centrifuged at 100,000g for 20 min at 4°C. The high-speed supernatant represented high salt soluble (HS) fraction. The pellet was washed in the same high salt buffer and re-extracted with high salt buffer containing 1% Triton-X100. The high-speed centrifugation produced the supernatant (HS/T fraction) and the pellet that was subsequently washed in HS/T buffer and re-extracted with RIPA buffer (50 mmol/L Tris-HCl, pH 8.0; 150 mmol/L NaCl; 5 mmol/L EDTA; 1% NP40; 0.5% SDS) as above to obtain RIPA soluble (RIPA) fraction. The final pellet was washed in RIPA buffer, resuspended in a gel loading buffer with 2% SDS and incubated in a boiling water bath for 10 min (SDS fraction). Aliquots of other fractions were mixed with an equal volume of 29 gel loading buffer and boiled for 5 min before loading on a 16% SDS-PAGE. The level of c-synuclein in fractions was assessed by Western blotting using SK109 rabbit-polyclonal antibody as described previously. 26 
Results
Immunohistochemical assessment of transverse spinal cord sections representing 31 sporadic and 23 familial cases revealed a group of nine sALS and eight fALS patients with unusual structures, which were intensely stained by two antibodies that recognize human c-synuclein ( Fig. 1A-D) . High specificity of SK109 antibody has been demonstrated in our previous studies 26, 27 and preincubation of antibodies with recombinant human c-synuclein (Fig. 1D) but not other recombinant synucleins (data not shown) abolished this staining. The occurrence of these c-synuclein-positive profiles was restricted to the corticospinal tract in the dorsolateral column of the spinal cord (Fig. 1A) . No such profiles were observed in any of studied 21 control spinal cord tissues from healthy individuals or patients with unrelated neurodegenerative diseases (see Materials and Methods and Table 1 for details). Occasional Corpora amylacea were detected within the corticospinal tracts, however, the morphology and distribution of these bodies did not match that of the c-synuclein-positive profiles. Generally round or slightly elliptical shape of profiles detected on transverse sections may suggest that they represent either small spheroidshaped structures or transsections of rod-like structures orientated along the spinal cord rostrocaudal axis. Immunostaining of longitudinal sections along the rostrocaudal axis of spinal cords prepared from re-orientated paraffin blocks of three patients with c-synuclein-positive profiles revealed elongated or rod-like c-synuclein-positive structures, which thickness (~10 lm) accurately correlated with the diameter of profiles seen on transverse sections (Fig. 1E) . Taking into consideration high abundance of c-synuclein in axons of many types of neurons [18] [19] [20] [21] it was feasible to suggest that observed structures represented damaged axons. However, double immunofluorescent staining demonstrated that these structures are negative for a pan-axonal neurofilament marker ( Fig. 2A and B) , indicating that they are not simply damaged axons but products of a more specific accumulation/aggregation process. Further double immunofluorescent or immunohistochemical staining of parallel sections with antibodies against c-synuclein and proteins that often aggregate in the nervous system of ALS patients demonstrated that c-synuclein-positive profiles detected within the dorsolateral column are negative for TDP-43, p62 and ubiquitin, although in a number of cases typical inclusions stained for these proteins were frequent in the anterior horn motor neurons in the same sections (Figs. 1F, G and 2C ). Retrospective analysis of the available clinical and histopathological data showed that in sALS these profiles were present not only in the more common cases with profound loss of upper motor neurons (observed in 4 of 11 analyzed cases), but also in cases with insignificant loss of these cells (observed in 4 of 5 analyzed cases). Furthermore, c-synuclein-positive profiles were detected in sALS cases with either mild or severe myelin pallor, suggesting that there is no correlation between their presence and the severity of damage to descending motor fibers.
Within the profiles the staining was observed to have a mesh-like appearance (Figs. 1, 2 ) suggesting that they might be composed of aggregated c-synuclein. To biochemically assess for the presence of aggregated c-synuclein species we carried out sequential protein fractionation on tissue samples dissected from the frozen spinal cord of a sALS patient histologically proven to be positive for c-synuclein-positive profiles in the dorsolateral column but not in the anterior horn (case 15). Western blot analysis of these protein fractions revealed the presence of c-synuclein in the detergentinsoluble fraction of tissues dissected from the dorsolateral column, but not from the anterior horn areas (Fig. 3) . The large amounts of c-synuclein seen in the soluble fractions should be attributed to high levels of this protein in multiple healthy or less damaged axons located in the dissected areas of the spinal cord. The presence of c-synuclein species with slow mobility in the denaturing SDS-PAGE was not typical even for the detergent-insoluble fractions, probably reflecting an intrinsic feature of aggregates formed by c-synuclein, as such high molecular mass species were previously found to be scarce even in the spinal cord samples of c-synuclein transgenic mice with a high burden of pathological c-synuclein aggregates. 18 Similar analysis detected c-synuclein in the detergent-insoluble fraction extracted from the dorsolateral column of another profiles-positive sALS case but not in a profiles-negative sALS or healthy control cases, representative Western blots are shown in Figure S1 . We also detected detergent-insoluble c-synuclein in the motor cortex of patients with FTLD-MND (Fig. S1) . DAPI-positive nuclei were occasionally observed in close proximity to c-synuclein-positive rod-like structures on longitudinal sections (Fig. 2A) . In transverse sections partial overlap of some nuclei with c-synuclein-positive profiles was seen (Fig. 2B and C) , suggesting that certain phagocytic cells envelop or internalize fragments of these structures. Internalization of axon-derived c-synuclein aggregates by specialized astrocytes in the optic nerve of a mouse model of glaucoma 28 and it is feasible that a similar process might take place in the dorsolateral column of the spinal cord of ALS patients. A staining pattern compatible with this hypothesis was revealed by co-immunostaining for c-synuclein and Mac-2/galectin-3 (Fig. 2D) , a marker of phagocytic cells, which has also been previously linked to ALS.
29
A pale diffuse cytoplasmic c-synuclein staining characteristic for spinal motor neuron cell bodies of healthy individuals is also typical for the majority of remaining spinal motor neurons in ALS patients (Fig. 4A) . However, in one sALS and three fALS cases with C9ORF72 repeat expansion (see Table 1 ) we found motor neurons with large c-synuclein-positive cytoplasmic inclusions (Fig. 4A  and B) . Only in one of these cases c-synuclein-positive profiles in the corticospinal tract were also present. No clinical characteristics that clearly distinct these four from other studied ALS cases were noted (Table S1) . Retrospective analysis of available histopathological data revealed that in spinal motor neurons of these four patients, p62-and TDP-43-positive inclusions were more abundant than rarely observed c-synuclein-positive inclusions, suggesting that these are different structures. We did not found cytoplasmic inclusions stained by c-synuclein antibody in upper motor neurons of several studied sALS cases but in one of them (case 18) c-synuclein-positive ballooned neuritis and amorphous extracellular deposits were observed in the motor cortex (Fig. 4C) . Finally, we also found no correlations between the presence of cytoplasmic inclusions or corticospinal tract profiles and the presence of human c-synuclein allelic variants encoding either valine or glutamic acid in the position 110 of the protein amino acid sequence (Table 1) .
Discussion
We identified a novel histopathological feature of ALS, c-synuclein-positive structures present in the spinal cord of approximately 30 percent of ALS patients we assessed. The most abundant (found in 17 of 58 cases included in this study) were pathological profiles that present exclusively in the dorsolateral column where the descending axons of upper motor neurons are localized. They have a distinct morphology and could be revealed by immunostaining with antibodies specific to c-synuclein, but not with antibodies to other proteins typically associated with ALS pathology. Large c-synuclein-positive inclusions in the cell bodies of some spinal motor neurons were observed in fewer ALS cases (4 of 58) and only in one case were both types of structures found.
Although c-synuclein is not a constituent of histopathological hallmarks in any neurodegenerative diseases, abnormal structures positive for this protein have been observed in the brain of some patients with Parkinson's disease, Lewy body dementia and Hallervorden-Spatz syndrome. 22, 23 However, the profiles we describe in the spinal cord of ALS patients are clearly different from previously described c-synuclein-positive structures in these diseases. The axonal spheroids seen in the stratum moleculare of the dentate gyrus of Parkinson's disease and Lewy repeat expansion using SK109 rabbit-polyclonal antibodies. In the motor cortex of a sALS patient (case 18), c-synuclein-positive ballooned neurites (left panel) and amorphous deposits (right panel) were detected using SK109 antibody. Scale bars = 50 lm for A, B and 10 lm for C. fALS, familial amyotrophic lateral sclerosis; sALS, sporadic amyotrophic lateral sclerosis.
body dementia cases were several times smaller and pretreatment of sections with formic acid was necessary for their detection. 23 Spheroids detected using an antibody against c-synuclein in the cingulate and midfrontal cortices of patients with Hallervorden-Spatz syndrome were also detected with antibodies to NF proteins and ubiquitin, 22 whereas c-synuclein-positive profiles in the dorsolateral column of ALS patients were negative for these proteins. Thus, these newly identified profiles represent a truly novel histopathological feature of neurodegenerative diseases. Because these profiles were found in both sALS, SOD1-fALS and C9ORF72-fALS cases it might be concluded that their formation is a common downstream event in pathogenesis of both sporadic and at least certain familial forms of ALS. Further, we suggest that csynuclein-positive profiles could be formed at early stages or in particular types of upper motor neuron atrophy due to their presence not only in cases with profound loss of upper motor neurons and severe damage to descending motor fibers, but also in cases with mild changes to these neurons and their axons.
The ability of wild type c-synuclein to form aggregates and fibrils in vivo has been previously demonstrated in mouse models. 18, 28 The presence of detergent-insoluble csynuclein species in the extracts from the profile-positive dorsolateral column but not from the profile-negative areas suggests the profiles observed in the spinal cord of ALS patients are also composed of aggregated c-synuclein.
Normally c-synuclein is abundant in axons of upper and lower motor neurons [18] [19] [20] [21] and therefore it is feasible to link the formation of the profiles with aggregation of c-synuclein in axons due to or followed by their structural damage. A rod-like appearance of these structures on longitudinal sections is consistent with this suggestion. However, absence of neurofilament proteins within profiles argues against a simple explanation that they are remnants of damaged axons. In the previous studies we have demonstrated the loss of neurofilament staining in axons of cultured neurons upon overexpression of c-synuclein 20 and decreased abundance of neurofilament proteins in the sciatic nerve of transgenic mice overexpressing this protein. 18, 25 Although a molecular mechanism linking abnormal levels of c-synuclein with disturbances of neurofilament metabolism or integrity of the neurofilament network is not clear, it is tempting to suggest that similar processes may contribute to the development of axonal pathology in ALS. It is feasible that at some stage of the pathology progression the local concentration of c-synuclein in axons of upper motor neurons might increase, which in turn might trigger the loss of neurofilaments and aggregation of accumulating csynuclein with both processes contributing to further axonal damage.
Transmission of aggregated, axon-derived c-synuclein species to a specific sub-class of astrocytes expressing Mac-2/galectin-3, a protein also linked to ALS, 29 has been recently demonstrated in the optic nerve of a mouse model of glaucoma, 28 which may explain previously observed accumulation of c-synuclein in the optic nerve astrocytes of human glaucoma patients. 24 Detection of some of the corticospinal tract c-synuclein-positive profiles within Mac-2/galactin-3-positive cells allowed us to hypothesize that a similar process involving phagocytic cells occurs in the spinal cord of some ALS patients.
The presence of c-synuclein-positive inclusions in the cell bodies of motor neurons, although rare, demonstrates that aggregation of this protein in neurons of ALS patients is not restricted to the axonal compartment. Both axonal pathology and cytoplasmic inclusions were also observed in transgenic mice overexpressing c-synuclein. 18, 25 Further studies should reveal relationships between the two types of pathological structures described here and their contribution to the pathogenesis of ALS. 
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